MA46898A - Compositions pour la conservation d'organes - Google Patents

Compositions pour la conservation d'organes

Info

Publication number
MA46898A
MA46898A MA046898A MA46898A MA46898A MA 46898 A MA46898 A MA 46898A MA 046898 A MA046898 A MA 046898A MA 46898 A MA46898 A MA 46898A MA 46898 A MA46898 A MA 46898A
Authority
MA
Morocco
Prior art keywords
compositions
organ conservation
conservation
organ
Prior art date
Application number
MA046898A
Other languages
English (en)
Inventor
Andrea Fekete
Ádám Hosszú
Ádám Vannay
Original Assignee
Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag filed Critical Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag
Publication of MA46898A publication Critical patent/MA46898A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046898A 2016-11-24 2017-11-24 Compositions pour la conservation d'organes MA46898A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1600639 2016-11-24

Publications (1)

Publication Number Publication Date
MA46898A true MA46898A (fr) 2019-10-02

Family

ID=89720188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046898A MA46898A (fr) 2016-11-24 2017-11-24 Compositions pour la conservation d'organes

Country Status (11)

Country Link
US (1) US12239125B2 (fr)
EP (1) EP3544420B8 (fr)
CN (1) CN110337244B (fr)
CA (1) CA3044746A1 (fr)
DK (1) DK3544420T3 (fr)
ES (1) ES2926179T3 (fr)
HU (1) HUE060027T2 (fr)
IL (1) IL266833B (fr)
MA (1) MA46898A (fr)
PL (1) PL3544420T3 (fr)
WO (1) WO2018096376A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140241A2 (fr) 2010-05-04 2011-11-10 The General Hospital Corporation Procédés et compositions pour la conservation de tissus et d'organes
US10918102B2 (en) 2014-03-13 2021-02-16 The General Hospital Corporation Devices and methods to improve and assess viability of human livers
WO2018232110A1 (fr) 2017-06-14 2018-12-20 The General Hospital Corporation Cryoconservation à très basse température
US12167729B2 (en) 2018-05-30 2024-12-17 The General Hospital Corporation Cryopreservation of tissues and organs
WO2022241417A1 (fr) * 2021-05-10 2022-11-17 The General Hospital Corporation Méthodes et compositions pour prolonger la conservation d'un organe et d'un tissu

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7503309A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL7503312A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4083978A (en) 1976-01-27 1978-04-11 Egyt Gyogyszervegyeszeti Gyar Oxime ethers
US5086054A (en) 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
US6297212B1 (en) * 1994-05-31 2001-10-02 Gregory M. Fahy Growth hormone therapy and related methods and pharmaceutical compositions
IN184685B (fr) * 1996-02-14 2000-09-23 Nat Inst Immunology
IN186677B (fr) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
US8765364B2 (en) 2007-05-18 2014-07-01 Lifeline Scientific, Inc. Ex vivo methods for validating substance testing with human organs and/or tissues
EP2230238B1 (fr) * 2008-01-04 2013-12-11 LG Life Sciences Ltd. Dérivés d'indole et d'indolazole possédant un effet de conservation de cellules, de tissus et d'organes
SE533552C2 (sv) * 2008-12-30 2010-10-26 Igeloesa Transplantation Science Ab Förfarande och lösning för behandling av en potentiell organdonator
AU2010269111B2 (en) 2009-07-09 2014-12-11 Ozteo Pty Ltd Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
JP5902148B2 (ja) * 2010-03-31 2016-04-13 アベラ ファーマスーティカルズ インコーポレイテッド 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤
SE534862C2 (sv) 2010-05-14 2012-01-24 Vivoline Medical Ab Användning av en medicinsk vätska för behandling av ett uttaget organ
EP2598508B1 (fr) * 2010-07-30 2015-04-22 Nerviano Medical Sciences S.r.l. Isoxazolo-quinazolines en tant que modulateurs de l'activité protéine kinase
WO2013051977A1 (fr) * 2011-10-03 2013-04-11 Vivoline Medical Ab Fluide médical comprenant une globuline et son utilisation pour la conservation d'organes collectés
GB201120259D0 (en) * 2011-11-24 2012-01-04 Univ Gent Allogeneic immune response control
US10842794B2 (en) 2014-02-07 2020-11-24 Támogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
CN106456578B (zh) 2014-02-07 2020-02-18 匈牙利科学院大学及其他机构附属研究所 Sigma-1受体激动剂化合物的用途
CN104292126B (zh) * 2014-08-14 2016-08-24 广东东阳光药业有限公司 萘衍生物及其在药物上的应用
US20170295776A1 (en) 2016-04-18 2017-10-19 University Of Cincinnati Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells

Also Published As

Publication number Publication date
EP3544420B8 (fr) 2022-11-23
HUE060027T2 (hu) 2023-01-28
IL266833B (en) 2022-01-01
CA3044746A1 (fr) 2018-05-31
CN110337244B (zh) 2023-07-21
CN110337244A (zh) 2019-10-15
US20190335745A1 (en) 2019-11-07
EP3544420A1 (fr) 2019-10-02
EP3544420B1 (fr) 2022-06-22
US12239125B2 (en) 2025-03-04
PL3544420T3 (pl) 2022-11-21
IL266833A (en) 2019-08-29
DK3544420T3 (da) 2022-09-05
WO2018096376A1 (fr) 2018-05-31
ES2926179T3 (es) 2022-10-24

Similar Documents

Publication Publication Date Title
EP3784285C0 (fr) Agents cryoprotecteurs pour formulations particulaires
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3446194A4 (fr) Raccourcis d'application pour carplay
EP3324840A4 (fr) Tensiomètre pour l'estimation de débit
EP3430731A4 (fr) Architecture d'iugw
MA71266A (fr) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
EP3630078A4 (fr) Agents pour chimio-embolisation
MA49006A (fr) Inhibiteurs d'ip6k
EP3265098A4 (fr) Compositions permettant de moduler l'expression de mecp2
EP3365403A4 (fr) Combinaison d'inhibiteurs de cobalt pour un bombage amélioré
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
EP3463259A4 (fr) Compositions d'écran solaire
EP3627918C0 (fr) Radiorecherche d'extension de couverture pour ec-gsm
EP3612173A4 (fr) Formulations pour la pulvérisation d'épinéphrine
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA46898A (fr) Compositions pour la conservation d'organes
MA39500A (fr) Compositions à base d'extraits de plantes pour l'inhibition de la 5-alpha-réductase
EP3403655A4 (fr) Composition pour augmenter l'expression de pgc-1
EP3560902A4 (fr) Composition pour marbre artificiel
EP3431808A4 (fr) Butée d'arrêt
IL269695A (en) Compounds useful as inhibitors of alcat 1
EP3302061A4 (fr) Compositions d'urée à libération prolongée
EP3408731A4 (fr) Modes d'interaction pour interactions objet-dispositif
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3444345A4 (fr) Dérivé d'arnmicro-143